CollabRx, Inc. (NASDAQ: CLRX) and OncoSolutions Cancer Center said they have announced a multiyear agreement.
CollabRx will provide its genetic variant annotation service to oncologists at OncoSolutions so they can glean insight from a patient´s tumor genetic profile to determine a treatment plan. This precision medicine approach to treatment planning is key to evaluating all possible therapy options to provide the best possible patient care and optimize clinical outcomes.
The GVA service pairs tumor genetic alterations derived from established next-generation sequencing platforms with concise textual narratives that describe drugs and clinical trials. It utilizes scientific data and other information, including clinical treatment guidelines, peer-reviewed publications, case reports and other sources of knowledge to develop actionable information for oncologists.
CollabRx is a recognized leader in cloud-based expert systems to inform healthcare decision-making. More information may be obtained at http://www.collabrx.com.
OncoSolutions is a private oncology practice based at Mount Elizabeth Novena Specialist Center in Singapore. More information may be obtained at http://www.oncosolutions.com.sg.